Progress in personalizing chemotherapy for bladder cancer

James S. Chang, Primo N Lara, Chong-Xian Pan

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology of bladder cancer has led to developments of molecular biomarkers that may help guide clinical decision making. These biomarkers, while promising, have not yet been validated in prospective trials and are not ready for clinical applications. As alkylating agents, platinum drugs kill cancer cells mainly through induction of DNA damage. A microdosing approach is currently being tested to determine if chemoresistance can be identified by measuring platinum-induced DNA damage using highly sensitive accelerator mass spectrometry technology. The hope is that these emerging strategies will help pave the road towards personalized therapy in advanced bladder cancer.

Original languageEnglish (US)
Article number364919
JournalAdvances in Urology
DOIs
StatePublished - 2012

Fingerprint

Platinum
Urinary Bladder Neoplasms
Drug Therapy
DNA Damage
Biomarkers
Alkylating Agents
Mass Spectrometry
Technology
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Urology

Cite this

Progress in personalizing chemotherapy for bladder cancer. / Chang, James S.; Lara, Primo N; Pan, Chong-Xian.

In: Advances in Urology, 2012.

Research output: Contribution to journalArticle

@article{642e42b2c82d462b967778147266a008,
title = "Progress in personalizing chemotherapy for bladder cancer",
abstract = "Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology of bladder cancer has led to developments of molecular biomarkers that may help guide clinical decision making. These biomarkers, while promising, have not yet been validated in prospective trials and are not ready for clinical applications. As alkylating agents, platinum drugs kill cancer cells mainly through induction of DNA damage. A microdosing approach is currently being tested to determine if chemoresistance can be identified by measuring platinum-induced DNA damage using highly sensitive accelerator mass spectrometry technology. The hope is that these emerging strategies will help pave the road towards personalized therapy in advanced bladder cancer.",
author = "Chang, {James S.} and Lara, {Primo N} and Chong-Xian Pan",
year = "2012",
doi = "10.1155/2012/364919",
language = "English (US)",
journal = "Advances in Urology",
issn = "1687-6369",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Progress in personalizing chemotherapy for bladder cancer

AU - Chang, James S.

AU - Lara, Primo N

AU - Pan, Chong-Xian

PY - 2012

Y1 - 2012

N2 - Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology of bladder cancer has led to developments of molecular biomarkers that may help guide clinical decision making. These biomarkers, while promising, have not yet been validated in prospective trials and are not ready for clinical applications. As alkylating agents, platinum drugs kill cancer cells mainly through induction of DNA damage. A microdosing approach is currently being tested to determine if chemoresistance can be identified by measuring platinum-induced DNA damage using highly sensitive accelerator mass spectrometry technology. The hope is that these emerging strategies will help pave the road towards personalized therapy in advanced bladder cancer.

AB - Platinum-based chemotherapy is commonly used for the treatment of locally advanced and metastatic bladder cancer. However, there are currently no methods to predict chemotherapy response in this disease setting. A better understanding of the biology of bladder cancer has led to developments of molecular biomarkers that may help guide clinical decision making. These biomarkers, while promising, have not yet been validated in prospective trials and are not ready for clinical applications. As alkylating agents, platinum drugs kill cancer cells mainly through induction of DNA damage. A microdosing approach is currently being tested to determine if chemoresistance can be identified by measuring platinum-induced DNA damage using highly sensitive accelerator mass spectrometry technology. The hope is that these emerging strategies will help pave the road towards personalized therapy in advanced bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=84858226599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858226599&partnerID=8YFLogxK

U2 - 10.1155/2012/364919

DO - 10.1155/2012/364919

M3 - Article

C2 - 22400017

AN - SCOPUS:84858226599

JO - Advances in Urology

JF - Advances in Urology

SN - 1687-6369

M1 - 364919

ER -